Artiria Medical builds a real-time deflectable guidewire technology intended for neurointerventional procedures to improve minimally invasive treatment of stroke. The company reports promising first-in-human results and has obtained FDA clearance. Its technology is already showing traction among neurointerventional physicians. Artiria secured financing to enable further clinical deployment and to complete its clinical studies. The recent financing mix underscores investor support as the company advances clinical work. Artiria Medical, an EPFL spin-off, has developed a neurovascular guiding system designed to navigate tiny brain arteries and speed delivery of life‑saving stroke therapies. The company says its technology integrates well into current clinical practice and addresses delays caused by challenging device navigation. With the new funding, Artiria plans to significantly advance the clinical and regulatory deployment of its first product. The announcement notes the company won Venture Kick and participated in Venture Leaders Life Science, which helped prepare fundraising and investor outreach. No revenue or user metrics were disclosed in the article. The financing is intended to accelerate clinical development and regulatory progress toward patient use. ARTIRIA Medical, an EPFL spin-off founded in August 2019 by Guillaume Petit‑Pierre and Marc Boers, has developed a patented micro‑actuated guidewire that facilitates micromotion deep in brain arteries to enable seamless navigation to cerebral lesions. The device aims to ease minimally invasive stroke procedures, reduce treatment duration, and improve patient outcomes against the backdrop of some 13 million annual strokes. The company plans to use its new funding to accelerate clinical validation and pursue regulatory approval of its first product. Less than one year after its foundation the start‑up closed a CHF 3 million financing to support those next stages. Leadership includes the two founders, and the company recently appointed Jacques Essinger, Jean‑Pierre Rosat, and Didier Cowling to its board to add medical device expertise.

Total raised

$14M

Funding rounds

5

Latest round

Series A

Latest activity

Feb 2024